Zierdiyeerkenaili_800_3  

PubMed:28596043 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T19 0-13 CI denotes Tildrakizumab
T3 21-28 CI denotes placebo
T36 55-71 DP denotes plaque psoriasis
T1 171-184 CI denotes Tildrakizumab
T37 319-335 DP denotes plaque psoriasis
T20 474-487 CI denotes tildrakizumab
T4 503-510 CI denotes placebo
T42 554-570 DP denotes plaque psoriasis
T39 872-888 DP denotes plaque psoriasis
T43 976-985 DP denotes Psoriasis
T21 1095-1108 CI denotes tildrakizumab
T22 1117-1130 CI denotes tildrakizumab
T5 1142-1149 CI denotes placebo
T23 1180-1193 CI denotes tildrakizumab
T24 1202-1215 CI denotes tildrakizumab
T6 1224-1231 CI denotes placebo
T41 1393-1402 DP denotes psoriasis
T2 1603-1616 CI denotes Tildrakizumab
T7 1762-1769 CI denotes placebo
T25 1773-1786 CI denotes tildrakizumab
T26 2508-2521 CI denotes tildrakizumab
T27 2537-2550 CI denotes tildrakizumab
T8 2570-2577 CI denotes placebo
T9 2728-2735 CI denotes placebo
T28 2776-2789 CI denotes tildrakizumab
T10 2800-2807 CI denotes placebo
T11 2954-2961 CI denotes placebo
T29 3002-3015 CI denotes tildrakizumab
T12 3026-3033 CI denotes placebo
T30 3097-3110 CI denotes tildrakizumab
T31 3126-3139 CI denotes tildrakizumab
T13 3155-3162 CI denotes placebo
T14 3337-3344 CI denotes placebo
T32 3432-3445 CI denotes tildrakizumab
T15 3456-3463 CI denotes placebo
T16 3696-3703 CI denotes placebo
T33 3791-3804 CI denotes tildrakizumab
T17 3815-3822 CI denotes placebo
T34 4012-4025 CI denotes tildrakizumab
T35 4202-4215 CI denotes tildrakizumab
T18 4265-4272 CI denotes placebo
T40 4373-4389 DP denotes plaque psoriasis